FDA Patient Affairs Office Needed To Improve Conflict Of Interest, NORD Says
Executive Summary
Elevating FDA's handling of patient-related issues could help ensure more patients get on advisory committees, rare disease advocates say, but agency notes that waivers are always an option.
You may also be interested in...
FDA Safety Meetings: Outpatient Drugs, Hypoglycemia Getting Limelight
US agency's events could address a touchy subject: how much responsibility does FDA have for preventing adverse events, and how much falls to physicians?
Puberty Blockers: FDA's Califf Asked If REMS, Boxed Warning Against Off-Label Use In The Works
FDA Commissioner Robert Califf tells House appropriations subcommittee chair the agency will 'consider any information that may be available' on off-label use of puberty blockers for gender dysphoria before making a regulatory decision.
ADHD Drugs: FDA Commissioner Blames Inappropriate Prescribing For Shortages
ADHD drug shortages may have resulted from industry reticence to fill DEA quotas, as well as a 'heavy element of professional responsibility' with off-label prescribing, Robert Califf told a House appropriations subcommittee.